September 18, 2018 / 11:23 AM / a month ago

Viking Therapeutics liver drug succeeds in mid-stage study

Sept 18 (Reuters) - Viking Therapeutics Inc said on Tuesday its experimental liver disease treatment met the main goals of a mid-stage trial by reducing cholesterol and liver fat in patients.

The 12-week study tested Viking's VK2809 against a placebo in patients with non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, or "bad cholesterol". (Reporting by Tamara Mathias in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below